Karyopharm Therapeutics (KPTI) Expected to Announce Quarterly Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($2.26) per share and revenue of $33.16 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Karyopharm Therapeutics Trading Up 4.3%

Shares of KPTI stock opened at $6.58 on Wednesday. The firm’s 50 day moving average is $6.83 and its 200-day moving average is $6.17. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.38. The firm has a market capitalization of $120.48 million, a price-to-earnings ratio of -0.45 and a beta of 0.21.

Analysts Set New Price Targets

KPTI has been the topic of several research reports. Wall Street Zen upgraded Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating for the company. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Finally, Royal Bank Of Canada decreased their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Institutional Trading of Karyopharm Therapeutics

Large investors have recently bought and sold shares of the company. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $45,000. XTX Topco Ltd bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at approximately $56,000. Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $163,000. ADAR1 Capital Management LLC purchased a new position in Karyopharm Therapeutics in the 3rd quarter worth approximately $164,000. Finally, Bank of America Corp DE increased its holdings in shares of Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the last quarter. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.